John A Stalfort III bought $11.2M of Verrica Pharmaceuticals (VRCA)

Executed Nov 22 2024, disclosed Nov 26 2024, 4 days later.

Value, as filed

$11.2M

as filed

Executed

Nov 22 2024

the trade date, as filed

Disclosed

Nov 26 2024

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

-34.0%

-28.3% from execution

Over the 21 trading sessions from the disclosed entry session (Nov 26 2024), the stock returned -34.0% (delay-adjusted); from the execution session (Nov 22 2024), -28.3%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

JI John A Stalfort III Director profile →

John A Stalfort III (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in VRCA. Across 1 priced purchase filing, the average 21-session return was -28.3% from execution and -34.0% from disclosure (delay-adjusted; derived). The largest single filing was $11.2M of VRCA (as filed, as filed), executed Nov 22 2024.

The name

VRCA VRCA VRCA · 5 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→